Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Scilex Holding CompanyNASDAQ: SCLX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $4.45M rose 221.3% year over year, ahead of the +7.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.
Context
- Cost of revenue amounted to 50.3% of revenue in FY2025, up 20.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +221.3% holds above the trailing-twelve-month pace of +7.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 15.22M USD
- Year-over-year change
- -8.8%
- 4-year CAGR
- +43.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.22M | -8.8% |
| FY2024 | 2024-12-31 | 16.69M | +6.4% |
| FY2023 | 2023-12-31 | 15.68M | +45.2% |
| FY2022 | 2022-12-31 | 10.8M | +197.1% |
| FY2021 | 2021-12-31 | 3.63M | — |
Cost of Revenue vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 cost of revenue of $15.25M is the 3rd highest of the 9 companies compared; the peer median is $6.61M.
- Its year-over-year change of +7.1% is the 2nd highest of 8, against a peer median of -22.4%.
- Cost of revenue amounts to 45.0% of revenue for SCLX, versus a peer median of 51.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.29M | -55.6% | -25.9% | 47.9% | |
| LTM Mar 2026 | $29.7M | -64.0% | — | 161.2% | |
| LTM Mar 2026 | $15.25M | +7.1% | +12.1% | 45.0% | |
| LTM Mar 2026 | $7.78M | -27.0% | -0.2% | 51.7% | |
| LTM Mar 2026 | $7.19M | +2.8% | +27.8% | 140.0% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $6.04M | -22.4% | — | 50.4% |
| LTM Mar 2026 | $2.24M | +39.7% | — | — | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $1.12M | — | — | 19.9% |
| LTM Mar 2026 | $46K | +4.5% | — | — | |
| Peer median (excluding SCLX) | $6.61M | -22.4% | -0.2% | 51.0% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 31.32M | 38.03M | 46.74M | 56.59M | 30.25M |
| Cost of Revenue | 3.63M | 10.8M | 15.68M | 16.69M | 15.22M |
| Gross Profit | 27.68M | 27.24M | 31.06M | 39.9M | 15.03M |
| Gross Margin | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| Research & Development | 9.2M | 9.05M | 12.75M | 9.64M | 20.71M |
| Selling, General & Admin | 50.58M | 64.9M | 119.64M | 119.02M | 266.63M |
| Operating Expenses | 63.52M | 77.87M | 136.49M | 123.3M | 287.34M |
| Depreciation & Amortization | 3.78M | 4.45M | 4.15M | 4.05M | 4.62M |
| EBITDA | (72.88M) | (9.3M) | (109.1M) | (66.8M) | (357.95M) |
| EBITDA Margin | -232.7% | -24.5% | -233.4% | -118.0% | -1183.2% |
| Operating Income | (35.84M) | (50.63M) | (105.43M) | (83.4M) | (272.3M) |
| Operating Margin | -114.4% | -133.1% | -225.6% | -147.4% | -900.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.76M | 9.6M | 1.07M | 1.96M | 11.46M |
| Other Income / Expenses | (52.58M) | 27.27M | (8.89M) | 10.59M | (101.72M) |
| Income Before Tax | (88.42M) | (23.36M) | (114.32M) | (72.81M) | (374.03M) |
| Pre-Tax Margin | -282.3% | -61.4% | -244.6% | -128.7% | -1236.3% |
| Income Tax Expense | 5K | 4K | 13K | (1K) | 26K |
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Net Margin | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |
| EPS (Basic) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| EPS (Diluted) | (23.29) | (6.09) | (44.85) | (19.43) | (36.48) |
| Weighted Avg Shares | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
| Weighted Avg Shares (Diluted) | 3.8M | 3.83M | 3.72M | 6.95M | 11.03M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.